Table 1. Baseline clinicopathological characteristics of patients with advanced gastric cancer.
| No. of patients | % | |
|---|---|---|
| Total no. | 43 | 100 |
| Age, years (median, range) | 51 (31–64) | |
| Gender | ||
| Male | 35 | 81.4 |
| Female | 8 | 18.6 |
| ECOG performance status | ||
| 0 | 17 | 39.5 |
| 1 | 26 | 60.5 |
| Histology | ||
| Well/moderately differentiated | 15 | 34.9 |
| Poorly differentiated or signet-ring cell type | 21 | 48.9 |
| Unknown | 7 | 16.3 |
| Metastasis sites | ||
| Liver | 22 | 51.2 |
| Peritoneum | 20 | 46.5 |
| Distant abdominal lymph nodes | 29 | 67.4 |
| Lung | 4 | 9.3 |
| Bone | 4 | 9.3 |
| No. of metastatic sites | ||
| 1 | 10 | 23.3 |
| 2 | 22 | 51.2 |
| ⩾3 | 11 | 25.6 |
| Prior gastrectomy | 15 | 34.9 |
| No. of previous treatment lines | ||
| 1 | 6 | 13.9 |
| 2 | 37 | 86.1 |
| First-line chemotherapy regimen | ||
| T | 2 | 4.6 |
| FP | 26 | 60.4 |
| FT | 3 | 7.0 |
| TP | 6 | 14.0 |
| FTP | 6 | 14.0 |
Abbreviations: ECOG=Eastern Cooperative Oncology Group; T=taxane (docetaxel); F=fluoropyrimidine (5-FU, capecitabine, or S-1); P=platinum (cisplatin or oxaliplatin).